GTAB B Stock Overview
A medical technology company, engages in the development, production, and sale of products for use in organ transplantation.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Glycorex Transplantation AB (publ) Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | SEK 1.00 |
| 52 Week High | SEK 0 |
| 52 Week Low | SEK 0 |
| Beta | 0.33 |
| 11 Month Change | 1.01% |
| 3 Month Change | 24.75% |
| 1 Year Change | -65.47% |
| 33 Year Change | -90.12% |
| 5 Year Change | -85.10% |
| Change since IPO | -76.24% |
Recent News & Updates
Shareholder Returns
| GTAB B | SE Medical Equipment | SE Market | |
|---|---|---|---|
| 7D | -5.8% | 0.3% | 0.2% |
| 1Y | -65.5% | -2.9% | 12.6% |
Return vs Industry: GTAB B underperformed the Swedish Medical Equipment industry which returned -0.7% over the past year.
Return vs Market: GTAB B underperformed the Swedish Market which returned 14.1% over the past year.
Price Volatility
| GTAB B volatility | |
|---|---|
| GTAB B Average Weekly Movement | 16.9% |
| Medical Equipment Industry Average Movement | 7.2% |
| Market Average Movement | 5.9% |
| 10% most volatile stocks in SE Market | 12.3% |
| 10% least volatile stocks in SE Market | 3.4% |
Stable Share Price: GTAB B has not had significant price volatility in the past 3 months.
Volatility Over Time: GTAB B's weekly volatility (17%) has been stable over the past year, but is still higher than 75% of Swedish stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1996 | 21 | Johan Laven | www.glycorex.se |
Glycorex Transplantation AB (publ), a medical technology company, engages in the development, production, and sale of products for use in organ transplantation. It develops a molecular level nanosurgical technology that specifically selects and removes antibodies in the blood focusing areas within transplants, blood transfusion, and blood products, as well as autoimmune disease. The company’s principal product is Glycosorb-ABO, which facilitates the transplantation of organs over the blood group barriers that is used for the blood group-incompatible kidney, liver, heart, lungs, pancreatic, and stem cells transplantation procedures.
Glycorex Transplantation AB (publ) Fundamentals Summary
| GTAB B fundamental statistics | |
|---|---|
| Market cap | SEK 73.71m |
| Earnings (TTM) | -SEK 29.54m |
| Revenue (TTM) | SEK 31.43m |
2.3x
P/S Ratio-2.5x
P/E RatioIs GTAB B overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| GTAB B income statement (TTM) | |
|---|---|
| Revenue | SEK 31.43m |
| Cost of Revenue | SEK 5.15m |
| Gross Profit | SEK 26.28m |
| Other Expenses | SEK 55.82m |
| Earnings | -SEK 29.54m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
Aug 29, 2024
| Earnings per share (EPS) | -0.40 |
| Gross Margin | 83.62% |
| Net Profit Margin | -93.99% |
| Debt/Equity Ratio | 2.1% |
How did GTAB B perform over the long term?
See historical performance and comparison